{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T08:56:23Z","timestamp":1784710583460,"version":"3.55.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003500","name":"University of Padova","doi-asserted-by":"crossref","award":["DOR n. 2208432\/2022"],"award-info":[{"award-number":["DOR n. 2208432\/2022"]}],"id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s40261-024-01350-6","type":"journal-article","created":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T15:03:30Z","timestamp":1709391810000},"page":"289-291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tolvaptan Treatment and Long-Term Impact on Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients: A Pilot Study"],"prefix":"10.1007","volume":"44","author":[{"given":"Gianni","family":"Carraro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Di Vico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loris","family":"Martinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Bettin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Cacciapuoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia Federica","family":"Stefanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gobbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Nalesso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Katiana","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7534-0128","authenticated-orcid":false,"given":"Lorenzo A.","family":"Cal\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,2]]},"reference":[{"key":"1350_CR1","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.pop.2020.08.010","volume":"47","author":"P Perumareddi","year":"2020","unstructured":"Perumareddi P, Trelka DP. autosomal dominant polycystic kidney disease. Prim Care. 2020;47:673\u201389.","journal-title":"Prim Care"},{"key":"1350_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000468956","volume":"190","author":"V Corradi","year":"2017","unstructured":"Corradi V, Giuliani A, Gastaldon F, de Cal M, Mancini B, Montaldi A, et al. Genetics and autosomal dominant polycystic kidney disease progression. Contrib Nephrol. 2017;190:117\u201323.","journal-title":"Contrib Nephrol"},{"key":"1350_CR3","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.xkme.2019.11.009","volume":"2","author":"N Nobakht","year":"2020","unstructured":"Nobakht N, Hanna RM, Al-Baghdadi M, Ameen KM, Arman F, Nobahkt E, et al. Advances in autosomal dominant polycystic kidney disease: a clinical review. Kidney Med. 2020;2:196\u2013208.","journal-title":"Kidney Med."},{"key":"1350_CR4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/ndt\/gfv456","volume":"3","author":"RT Gansevoort","year":"2016","unstructured":"Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, et al. Recom-mendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant. 2016;3:337\u201348.","journal-title":"Nephrol Dial Transplant"},{"key":"1350_CR5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/ndt\/gfx043","volume":"33","author":"VE Torres","year":"2018","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, et al. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant. 2018;33:477\u201389.","journal-title":"Nephrol Dial Transplant"},{"key":"1350_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2147\/IJNRD.S125942","volume":"11","author":"L Sans-Atxer","year":"2018","unstructured":"Sans-Atxer L, Joly D. Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations. Int J Nephrol Renovasc Dis. 2018;11:41\u201351.","journal-title":"Int J Nephrol Renovasc Dis."},{"key":"1350_CR7","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1136\/bmj.306.6890.1437","volume":"306","author":"C Jenkinson","year":"1993","unstructured":"Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ. 1993;306:1437\u201340.","journal-title":"BMJ"},{"key":"1350_CR8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/nur.20247","volume":"31","author":"MA Hertzog","year":"2008","unstructured":"Hertzog MA. Considerations in determining sample size for pilot studies. Res Nurs Health. 2008;31:180\u201391.","journal-title":"Res Nurs Health"},{"key":"1350_CR9","unstructured":"OpenEpi (Open Source Epidemiologic Statistics for Public Health). https:\/\/www.openepi.com\/SampleSize\/SSMean.htm. Accessed 20 Feb 2024."},{"key":"1350_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.xkme.2019.11.008","volume":"2","author":"MA Anderegg","year":"2020","unstructured":"Anderegg MA, Dhayat NA, Sommer G, Semmo M, Huynh-Do U, Vogt B, et al. Quality of Life in autosomal dominant polycystic kidney disease patients treated with tolvaptan. Kidney Med. 2020;2:162\u201371.","journal-title":"Kidney Med."},{"key":"1350_CR11","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/ndt\/gfv299","volume":"31","author":"RJ Simms","year":"2016","unstructured":"Simms RJ, Thong KM, Dworschak GC, Ong AC. Increased psychosocial risk, depression and reduced quality of life living with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2016;31:1130\u201340.","journal-title":"Nephrol Dial Transplant"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01350-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-024-01350-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01350-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T02:19:11Z","timestamp":1711765151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-024-01350-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,2]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1350"],"URL":"https:\/\/doi.org\/10.1007\/s40261-024-01350-6","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,2]]},"assertion":[{"value":"18 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"This study has been supported in part by grant DOR n. 2208432\/2022 from the University of Padova to LAC.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Gianni Carraro, Valentina Di Vico, Loris Martinetti, Elisabetta Bettin, Martina Cacciapuoti, Lucia Federica Stefanelli, Laura Gobbi, Federico Nalesso, Francesca Katiana Martino and Lorenzo A. Cal\u00f2 have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Although the anonymization process prevented any possible transmission of patients\u2019 sensible data, to further save the privacy of the patients involved in the study, the data will be made available from the corresponding author upon reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data And Materials"}},{"value":"Ethical review and approval were waived for this study, as permitted for a retrospective clinical investigation; the local Ethics Committee was informed.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all participants.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"Patient consent was obtained by telephone before analysis of the data. Furthermore, subjects were not exposed to any risk by the irreversible anonymization of data. The anonymization process prevented any possible transmission of sensible data, saving subject privacy.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Conceptualization: GC, VDV, LAC. Investigation: VDV, LM, EB, MC, LFS, LG, FKM. Data curation: VDV, LM, EB, MC, LFS, LG, FN, FKM. Data analysis: LG, FKM. Supervision: LAC. Writing\u2014original draft preparation: GC, FKM, VDV, LG. Writing\u2014review and editing: FKM, FN, LAC. Funding acquisition: LAC. All authors have read and agreed to the final version of the manuscript.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}